Diagnosis of local recurrence after radical prostatectomy

Scattoni, Vincenzo; Montorsi, Francesco; Picchio, Maria; Roscigno, Marco; Salonia, Andrea; Rigatti, Patrìzio; Fazio, Ferruccio

doi:10.1111/j.1464-410x.2003.04692.x

Cited by 62 publications

(31 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…3 While these therapies are relatively effective in the short term, a significant proportion of patients who initially present with localized disease ultimately relapse. 4 The use of conditionally replicating adenoviruses (CRADs) offers an attractive strategy for cancer treatment, since it allows for selective replication of viruses in defined target cells and thereby augments the spread of therapeutic gene expression. 5 In order to make CRADs tumor-or tissue-specific, two strategies are employed.…”

Section: Introductionmentioning

confidence: 99%

An oncolytic conditionally replicating adenovirus for hormone-dependent and hormone-independent prostate cancer

et al. 2005

View full text Add to dashboard Cite

The use of conditionally replicating adenoviruses offers an attractive complementary treatment strategy for localized prostate cancer. We have produced a replicating adenovirus, Ad[I/PPT-E1A], where E1A gene expression is controlled by a recombinant regulatory sequence designated PPT. The PPT sequence comprises a PSA enhancer, a PSMA enhancer and a T-cell receptor g-chain alternate reading frame protein promoter, and it is shielded from transcriptional interference from adenoviral backbone sequences by an H19 insulator. Ad[I/PPT-E1A] yields prostate-specific E1A protein expression, viral replication and cytolysis in vitro. Furthermore, Ad[I/PPT-E1A] considerably regresses the growth of subcutaneous LNCaP prostate cancer tumors in nude mice. Importantly, the viral replication and cytolytic effect of Ad[I/PPT-E1A] are independent of the testosterone levels in the prostate cancer cells. This may be beneficial in a clinical setting since many prostate cancer patients are treated with androgen withdrawal. In conclusion, Ad[I/PPT-E1A] may prove to be useful in the treatment of localized prostate cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

An oncolytic conditionally replicating adenovirus for hormone-dependent and hormone-independent prostate cancer

et al. 2005

View full text Add to dashboard Cite

show abstract

“…Several studies have suggested a poor sensitivity of TRUS for patients with low PSA levels (33)(34)(35)(36)(37)(38). In addition, Koppie questioned a predictive value of TRUS-guided biopsy of the prostatic fossa, since a positive anastomotic biopsy was not associated with an improved outcome after salvage RT (39).…”

Section: R a D I O L O G I C A L I N V E S T I G A T I O N S F O R P mentioning

confidence: 99%

Salvage Radiotherapy for Patients with PSA Relapse Following Radical Prostatectomy: Issues and Challenges

Choo

2010

Cancer Res Treat

View full text Add to dashboard Cite

“…The PSA kinetics may be helpful in this context but cannot provide certainty, especially in single lymph node metastases (LNM) or low PSA increase [1,2] . Computed tomography (CT) and magnetic resonance tomography (MRT) display equal unreliability in the early detection of a localized or lymph node (LN) recurrence [3] .…”

Section: Introductionmentioning

confidence: 99%

First Results of [<sup>11</sup>C]choline PET/CT-Guided Secondary Lymph Node Surgery in Patients with PSA Failure and Single Lymph Node Recurrence after Radical Retropubic Prostatectomy

et al. 2010

View full text Add to dashboard Cite

Introduction: [¹¹C]choline PET/CT provides the opportunity to detect small lymph node metastases (LNM) (>5 mm) in prostate cancer (PCa) with exact topographic allocation. PSA development after resection of single LN recurrence detected via [¹¹C]choline PET/CT without adjuvant therapy is not yet analyzed. We wanted to evaluate the potential of [¹¹C]choline PET/CT in the diagnosis of single LN recurrence after radical prostatectomy (RPE) and whether secondary resection can result in PSA remission. Methods: We investigated 6 patients with biochemical recurrence (PSA: median 2.04, range 0.67–4.51 ng/ml) after RPE. A single suspicious LN was detected on PET/CT without suspicion of local relapse or distant metastasis. The suspicious and nearby LN were open dissected (09/2004–02/2008). Histological and PET/CT findings were compared and the postoperative PSA development was examined. Results: All metastasis-suspicious LN could be confirmed histologically. The additionally removed 10 LN were all correctly negative for cancer. Three patients showed a complete permanent PSA remission (<0.01 (n = 2), <0.03 ng/ml (n = 1)) without adjuvant therapy (follow-up: median 24, range 21–35 months). Conclusions: In this small selected collective [¹¹C]choline PET/CT achieved reliable results. After resection of single LNM in all patients the oncologic criteria of a remission were fulfilled. Three of 6 patients had a complete PSA remission without adjuvant therapy. Whether cure or a positive influence on the course of disease can be achieved in individual patients has to be shown in further studies.

show abstract

Diagnosis of local recurrence after radical prostatectomy

Cited by 62 publications

References 71 publications

An oncolytic conditionally replicating adenovirus for hormone-dependent and hormone-independent prostate cancer

An oncolytic conditionally replicating adenovirus for hormone-dependent and hormone-independent prostate cancer

Salvage Radiotherapy for Patients with PSA Relapse Following Radical Prostatectomy: Issues and Challenges

First Results of [<sup>11</sup>C]choline PET/CT-Guided Secondary Lymph Node Surgery in Patients with PSA Failure and Single Lymph Node Recurrence after Radical Retropubic Prostatectomy

Contact Info

Product

Resources

About